OncoMatch/Clinical Trials/NCT07322094
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Is NCT07322094 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including TORL-1-23 and paclitaxel and TORL-1-23 and carboplatin for figo stage iii and iv ovarian cancer.
Treatment: TORL-1-23 and paclitaxel · TORL-1-23 and carboplatin · TORL-1-23, paclitaxel, and carboplatin — A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: CLDN6 expression
Positive for claudin 6 (CLDN6) expression
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
FIGO Stage III or IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy for the disease under study
Prior systemic treatment for the disease under study
Cannot have received: surgery
Prior surgery
Cannot have received: radiation therapy to the abdomen or pelvis
Prior radiation therapy to the abdomen or pelvis
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence St. Jude Medical Center · Fullerton, California
- City of Hope · Irvine, California
- University of Southern California · Los Angeles, California
- UCLA · Los Angeles, California
- The Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07322094 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CLDN6?
Yes, CLDN6 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages